Determination of Cutpoints for Symptom Burden in Oncology Patients Receiving Chemotherapy

被引:10
作者
Miaskowski, Christine [1 ]
Paul, Steven M. [1 ]
Harris, Carolyn S. [1 ]
Shin, Joosun [1 ]
Oppegaard, Kate [1 ]
Conley, Yvette P. [2 ]
Hammer, Marilyn [3 ]
Kober, Kord M. [1 ]
Levine, Jon D. [4 ]
机构
[1] Univ Calif San Francisco, Sch Nursing, San Francisco, CA 94143 USA
[2] Univ Pittsburgh, Sch Nursing, Pittsburgh, PA 15261 USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Univ Calif San Francisco, Sch Med, San Francisco, CA USA
关键词
Symptom burden; cutpoints; chemotherapy; cancer; symptoms; severity; QUALITY-OF-LIFE; CONNOR-DAVIDSON RESILIENCE; CANCER PAIN; EVENT SCALE; STRESS; PREVALENCE; VALIDATION; SEVERITY; FATIGUE; INSTRUMENT;
D O I
10.1016/j.jpainsymman.2021.07.018
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Context. Cutpoints can be used as a threshold for screening symptom (s) that warrant intervention (s) and for monitoring patients' responses to these interventions. Objectives. In a sample of oncology patients undergoing chemotherapy, study purposes were to determine the optimal cutpoints for low, moderate, and high symptom burden and determine if these cutpoints distinguished among the symptom groups in any demographic, clinical, and stress characteristics, as well as QOL outcomes. Methods. Total of 1329 patients completed a modified version of the Memorial Symptom Assessment Scale (38 symptoms). Using the methodology of Serlin and colleagues, cutpoints were created using symptom occurrence rates and cancer-specific quality of life (QOL) scores. Cutpoints were validated using measures of stress and resilience and a generic measure of QOL (i. e., Medical Outcomes Study Short Form 12 (SF-12)). Results. Of the 25 possible cutpoints evaluated, the optimal cutpoint, with the largest between category F statistic, was CP8,15 (Low = 0-8, Moderate = 9-15, High = 16-38 symptoms). Percentage of patients in the Low, Moderate, and High cutpoint groups were 25.3%, 36.3%, and 38.4%, respectively. Significant differences were found among the symptom burden groups in global, cancer-specific, and cumulative life stress (i.e., Low < Moderate < High) and resilience and SF-12 (i.e., Low > Moderate > High) scores. Conclusion. Our findings provide evidence for clinically meaningful cutpoints that can be used to guide symptom assessment and management. These cutpoints may be used to establish alert thresholds for electronic monitoring of symptoms in oncology patients. (C) 2021 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:42 / 51
页数:10
相关论文
共 52 条
[1]   Quality of life, symptom experience and distress of lung cancer patients undergoing chemotherapy [J].
Akin, Semiha ;
Can, Gulbeyaz ;
Aydiner, Adnan ;
Ozdilli, Kursat ;
Durna, Zehra .
EUROPEAN JOURNAL OF ONCOLOGY NURSING, 2010, 14 (05) :400-409
[2]   Prevalence of Fatigue in Patients With Cancer: A Systematic Review and Meta-Analysis [J].
Al Maqbali, Mohammed ;
Admin, Dip ;
Al Sinani, Mohammed ;
Al Naamani, Zakariya ;
Al Badi, Khalid ;
Tanash, Mu'ath Ibrahim .
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2021, 61 (01) :167-+
[3]   Patient factors and quality of life outcomes differ among four subgroups of oncology patients based on symptom occurrence [J].
Astrup, Guro Lindviksmoen ;
Hofso, Kristin ;
Bjordal, Kristin ;
Guren, arianne Gronlie ;
Vistad, Ingvild ;
Cooper, Bruce ;
Miaskowski, Christine ;
Rustoen, Tone .
ACTA ONCOLOGICA, 2017, 56 (03) :462-470
[4]   Benefits of Digital Symptom Monitoring With Patient-Reported Outcomes During Adjuvant Cancer Treatment [J].
Basch, Ethan ;
Leahy, Allison B. ;
Dueck, Amylou C. .
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (07) :701-+
[5]   Clinical Utility and User Perceptions of a Digital System for Electronic Patient-Reported Symptom Monitoring During Routine Cancer Care: Findings From the PRO-TECT Trial [J].
Basch, Ethan ;
Stover, Angela M. ;
Schrag, Deborah ;
Chung, Arlene ;
Jansen, Jennifer ;
Henson, Sydney ;
Carr, Philip ;
Ginos, Brenda ;
Deal, Allison ;
Spears, Patricia A. ;
Jonsson, Mattias ;
Bennett, Antonia V. ;
Mody, Gita ;
Thanarajasingam, Gita ;
Rogak, Lauren J. ;
Reeve, Bryce B. ;
Snyder, Claire ;
Kottschade, Lisa A. ;
Charlot, Marjory ;
Weiss, Anna ;
Bruner, Deborah ;
Dueck, Amylou C. .
JCO CLINICAL CANCER INFORMATICS, 2020, 4 :947-957
[6]   Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment [J].
Basch, Ethan ;
Deal, Allison M. ;
Dueck, Amylou C. ;
Scher, Howard I. ;
Kris, Mark G. ;
Hudis, Clifford ;
Schrag, Deborah .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 318 (02) :197-198
[7]  
Berger A.M., 2020, NCCN Guidelines Version 1.2020 - Cancer-Related Fatigue
[8]   THE ALCOHOL-USE DISORDERS IDENTIFICATION TEST (AUDIT) - VALIDATION OF A SCREENING INSTRUMENT FOR USE IN MEDICAL SETTINGS [J].
BOHN, MJ ;
BABOR, TF ;
KRANZLER, HR .
JOURNAL OF STUDIES ON ALCOHOL, 1995, 56 (04) :423-432
[9]   Psychometric analysis and refinement of the Connor-Davidson Resilience Scale (CD-RISC): Validation of a 10-item measure of resilience [J].
Campbell-Sills, Laura ;
Stein, Murray B. .
JOURNAL OF TRAUMATIC STRESS, 2007, 20 (06) :1019-1028
[10]   Neuroinflammation and depressive disorder: The role of the hypothalamus [J].
Cernackova, Alena ;
Durackova, Zdenka ;
Trebaticka, Jana ;
Mravec, Boris .
JOURNAL OF CLINICAL NEUROSCIENCE, 2020, 75 :5-10